The Latest Cardiac and Vascular News
NEW YORK, Aug. 06, 2019 (GLOBE NEWSWIRE) — Pomerantz LLP announces that a class action lawsuit has been filed against ABIOMED, Inc. (“ABIOMED” or the “Company”) (NASDAQ: ABMD) and certain of its officers. The class action, filed in United States District Court, for the Southern District of New York, and […]
SAN CARLOS, Calif., Aug. 06, 2019 (GLOBE NEWSWIRE) — BioCardia, Inc. (NasdaqCM: BCDA, BCDAW), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced the closing of its previously announced public offering of 1,666,667 units at a price to the public of $6.00 per unit. Each unit issued […]
SUNNYVALE, Calif., Aug. 06, 2019 (GLOBE NEWSWIRE) — Silk Road Medical, Inc. (Nasdaq: SILK) (“Silk Road Medical”), a company focused on reducing the risk of stroke and its devastating impact, announced today the commencement of a proposed underwritten public offering of 3,500,000 shares of its common stock by certain selling stockholders. […]
WALTHAM, Mass., Aug. 07, 2019 (GLOBE NEWSWIRE) — Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company that has historically focused on the development of novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular disease, today announced its financial results for the quarter ended June 30, 2019, and recent […]
BASKING RIDGE, N.J. and MEMPHIS, Tenn., Aug. 07, 2019 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select cardiovascular and autoimmune diseases, and Cognate BioServices, Inc. (“Cognate”), a leading contract development and manufacturing organization in […]
PHILADELPHIA–(BUSINESS WIRE)–XyloCor Therapeutics, a private clinical-stage biopharmaceutical company focused on the development of gene therapy for unmet needs in cardiovascular disease, strengthens its leadership team with the appointment of Rickey Reinhardt, MD, PhD, as Chief Medical Officer. Dr. Reinhardt formerly served as Chief Medical Officer for Comet Therapeutics where he […]
SANTA CLARA, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended June 30, 2019. Recent Highlights Recognized revenue of $10.0 million […]
– As reported, revenues of $4.350 billion increased 1.7 percent. – On a comparable, currency-neutral basis, revenues increased 5.7 percent. – As reported, diluted earnings per share of $1.51 decreased 25.6 percent. – As adjusted, diluted earnings per share of $3.08 increased 5.8 percent, or 14.8 percent on a currency-neutral […]
ST. PAUL, Minn.–(BUSINESS WIRE)–Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that it has acquired the WIRION Embolic Protection System and related assets from Gardia Medical Ltd., a wholly owned Israeli […]
SAN RAMON, Calif., Aug. 6, 2019 /PRNewswire/ — BioVentrix, Inc., a pioneer of technologies and procedures for the less invasive treatment of heart failure (HF), today announced two significant additions to its executive team. Thasee Pillay, MBChB has been named Chief Medical Officer for Europe and William Abbott has been named Chief Financial Officer. “The appointments of […]
